Apply to Trial

Compensation: Varies

Number of Visits: Unknown

76 Participants Needed

Immunization Response for Childhood Cancer Survivors

Recruiting at 1 trial location

Age: < 65

Sex: Any

Trial Phase: Phase 2

Sponsor: Memorial Sloan Kettering Cancer Center

Must not be taking: Immunosuppressive drugs, Rituximab

Disqualifiers: Pregnancy, HIV, HCT, others

No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This study will look at your body's response to the new immunizations. We want to see how well they will protect you. Immunization is the same as vaccination. Our goal is to protect you as much as we can. We do not want you to have the measles, mumps, or whooping cough. We are doing the study because there is no standard way to re-immunize people after cancer treatments.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, if you are on immunosuppressive drugs, you cannot participate in the trial.

Is it safe for childhood cancer survivors to receive vaccinations after treatment?

Research shows that revaccinating childhood cancer survivors after treatment is generally safe and can help restore protective antibody levels. Most patients respond well to revaccination, indicating their immune systems can recover and handle vaccines safely.¹ ² ³ ⁴ ⁵

How is the Immunization Schedule treatment unique for childhood cancer survivors?

The Immunization Schedule for childhood cancer survivors is unique because it uses a response-based approach to tailor vaccine schedules, starting vaccinations 3 months after treatment ends to ensure protective antibody levels, unlike standard guidelines which are not universally approved.¹ ² ³ ⁶ ⁷

What data supports the effectiveness of the treatment Immunization Schedule for childhood cancer survivors?

A study showed that revaccinating childhood cancer survivors three months after completing treatment resulted in protective antibody levels for most vaccines, indicating that a tailored immunization schedule can be effective for these patients.¹ ² ³ ⁶ ⁸

Who Is on the Research Team?

Nancy Kernan, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Are You a Good Fit for This Trial?

This trial is for childhood cancer survivors aged 3 to 24 months post-chemotherapy, under 18 at diagnosis. They must be in remission with no active infections or HIV, not pregnant or breastfeeding, and able to consent. Excluded are those with low Karnofsky scores, prior stem cell transplants, vaccine allergies, on immunosuppressants, allergic to latex or who've had Rituximab.

Inclusion Criteria

I finished my chemotherapy for cancer between 3 to 24 months ago.

My gender or ethnic background does not limit my participation.

Patients or their guardians must be able to understand the nature and risk of the proposed study and be able to sign consent.

See 4 more

Exclusion Criteria

I am HIV positive.

My health status is below 70% on the Karnofsky scale.

I have had a stem cell transplant from myself or a donor.

See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Immunization

Participants receive new immunizations to evaluate their body's response and protection against diseases like measles, mumps, and whooping cough

6-8 weeks

Follow-up

Participants are monitored for safety and effectiveness of the immunizations after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

Immunization Schedule

Trial Overview The study tests how well new vaccination schedules work for young cancer survivors of different age groups: below 7 years old; between 7 and less than 11 years old; and those aged 11 and above. It aims to establish a standard re-immunization process against diseases like measles.

How Is the Trial Designed?

3Treatment groups

Experimental Treatment

Group I: CExperimental Treatment1 Intervention

Immunization Schedule patients \> or = to 11 years of age

Group II: BExperimental Treatment1 Intervention

Immunization Schedule patients \> or = to 7 years and \<11 years of age

Group III: AExperimental Treatment1 Intervention

Immunization Schedule patients \<7 years.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials

1,998

Recruited

602,000+

Published Research Related to This Trial

A response-based re-vaccination schedule for non-transplant pediatric cancer survivors was tested, showing that most patients developed protective antibody levels after receiving vaccines 3 months post-treatment.

This approach suggests that vaccination can be effectively tailored to the individual immune recovery of pediatric cancer survivors, enhancing their protection against infections.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Dynamic re-immunization of off-treatment childhood cancer survivors: An implementation feasibility study.Han, JH., Harmoney, KM., Dokmeci, E., et al.[2018]

Children with acute lymphocytic leukemia (ALL) experience a temporary reduction in specific antibody levels after intensified chemotherapy, with protection levels for various vaccines ranging from 17% to 100%.

Most children showed a positive response to revaccination, indicating that while chemotherapy affects immunity, their immunological memory is preserved and can be restored with additional vaccinations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Loss of antibodies and response to (re-)vaccination in children after treatment for acute lymphocytic leukemia: a systematic review.van Tilburg, CM., Sanders, EA., Rovers, MM., et al.[2018]